medigraphic.com
ISSN 1405-8871 (Print)

2019, Number 2

<< Back Next >>

Aten Fam 2019; 26 (2)

Sociocultural Factors Involved in the Rejection of the Use of Insulin

Ávalos AH, Morfín MCJ, Ung MEA

Language: Spanish
References: 19
Page: 58-62
PDF size: 182.39 Kb.


ABSTRACT

Objective: To determine the sociocultural factors involved in the rejection of the use of insulin in patients with diabetes mellitus type 2 (DM2). Methods: A cross-sectional study conducted from March 2015 to February 2018. 314 patients were studied, diagnosed with dm2 in the Family Medicine Unit (FMU) No. 58 of the Mexican Social Security Institute (IMSS) in Tepalcatepec Michoacán, México. Prior signed consent, a demographic data survey and the Graffar-Méndez Castellanos scale were applied. Descriptive statistics for the analysis of the studied variables was used. Results: the studied population included 179 women (57%) and 135 men (43%); schooling was null or basic in 211 participants (67.2%); 141 were dedicated to housework (44.9%), and 233 were workers (74.2%). 211 participants mentioned that they were proposed to use insulin (67.19%), however, they referred not receiving relevant information from health personnel about this treatment; the reason for the rejection of insulin use was fear of blindness in 127 patients (40.4%), most of them only had basic education and a low socio-economic level. Conclusions: There is a false belief in the use of insulin in patients who are afraid of becoming blind, which was related to low socio-economic education, as well as the lack of appropriate information by health personnel, factors that contribute to the delay in insulinisation with all the health consequences that this entails.


REFERENCES

  1. Rivera J, Gutiérrez J, Rodríguez M. Ensanut. Resultados Nacionales 2012. Instituto Nacional de Salud Pública. 2012;23-174.

  2. Ananya M. Historia de la Diabetes. N Med. 2015;1:15-8.

  3. Roldán B, Ayuso C, González C, Matos S, Escobar F. Is monitoring type II diabetes mellitus different in urban and rural environments? Rev. Clin. Med. Fam. 2012;5(2):104-10.

  4. dof. Norma Oficial Mexicana nom-015-SSA2-2010, Para la prevención, tratamiento y control de la diabetes mellitus. [Internet] [citado en 2018 Ene 20]. Disponible en http://www.dof.gob.mx/normasOficiales/4215/salud/salud.htm

  5. Dickerson L, Ye X, Sack J, Hueston W. Glycemic control in medical in patients with type 2 Diabetes mellitus receiving sliding scale insulin regimens versus routine diabetes medications: a multicenter randomized controlled trial. Ann Fam Med. 2003;1(1):29-35.

  6. Shubrook J. Insulin for type 2 diabetes: how and when to get started: with guidelines now calling for initiation of basal insulin for patients who are not at goal a year after diagnosis, familiarity with optimal timing, dosing, and titration is critical for family physicians. J Fam Pract. 2014;63(2):76-81.

  7. Hayes R, Fitzgerald J, Jacober S. Primary care Physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract. 2008;62(6):860-68.

  8. Zarate A, Hernández V, Saucedo R. Manejo de la Diabetes Mellitus tipo 2. Rev. Acta med Ángeles. 2008;2:91-92.

  9. Hayat A, Shaikh N. Barriers and myths to initiate insulin therapy for type 2 diabetes mellitus at primary health care centers of Hyderabad District. World Applied Sciences Journal. 2010;8(1):66-72.

  10. Lagunes R, Galindo I, Castillo A, Romero C, Rosas F. ¿Por qué los médicos no utilizan en forma temprana la insulinización en pacientes con diabetes mellitus tipo 2? Un estudio cualitativo en una ciudad mexicana. Salud Colec. 2017;13(4):693-712.

  11. Abdulaziz B, Chenoweth I. Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes. 2017;8(1):28-39.

  12. American Diabetes Association. The Journal of clinical and applied research and education: Diabetes care. 2018

  13. Balcázar P, Bonilla M, Gurrola G, Virseda J, Ortiz P. La experiencia de vivir con diabetes: un abordaje cualitativo. Diabet Hoy Med Sal. 2007;8(2):1799.

  14. Rosas J, Ruy L. Documento de posición de ALAD con aval de Sociedades de Diabetes y Endocrinología Latinoamericanas para el tratamiento de la Diabetes Tipo 2. Rev. Endoc Nutr. 2010;18(2):108-19.

  15. Conget I, Giménez M. Insulinización temprana: ¿a favor o en contra? Avances en Diabetología. Av. Diabetol. 2008;24(6):507-508.

  16. Narihito Y. Psychological reluctance to Insulin therapy: as an illness side of diabetes mellitus. Diabetology International. 2018;9(2):82-3

  17. Ponte K. Barreras para la insulinización precoz en pacientes diabéticos tipo 2 atendidos en el módulo de Diabetes del Hospital Hipólito Unanue y Centros de salud de Tacna. Universidad Privada de Tacna. 2017.

  18. Moreno J, Velasco A, Matallana M. Síndrome metabólico en niños y adolescentes. Rev Gastro. 2014;16(2):121-31.

  19. Acosta R, García B, Saldaña V. Concepciones culturales sobre insulinoterapia de pacientes diabéticos tipo 2. Rev Salud Pública Nutr. 2012;13(1):1.




2020     |     www.medigraphic.com